Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEyOND: BETA-TT8 in wetAMD
NCT07766473Phase 2Not yet recruiting
- Sponsor
- Filamon Limited
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of BETA-TT8 in neovascular age-related macular degeneration (NVAMD), sponsored by Filamon Limited. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BETA-TT8
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07766473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07766473.